ADC Therapeutics SA (ADCT) Tops Q2 EPS by 11c

ADC Therapeutics SA (NYSE: ADCT) reported Q2 EPS of ($0.11), $0.11 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $19.25 million versus the consensus estimate of $18.89 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• Live Ventures (LIVE) Reports Q3 Loss of $0.34
• Studio City International Holdings Limited (MSC) Reports Q2 Loss of $0.02